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Abstract
This study investigated whether vitamin D is associated with the presence or severity of chronic tic disorders and their psy-
chiatric comorbidities. This cross-sectional study compared serum 25-hydroxyvitamin D [25(OH)D] (ng/ml) levels among 
three groups: children and adolescents (3–16 years) with CTD (n = 327); first-degree relatives (3–10 years) of individuals with 
CTD who were assessed for a period of up to 7 years for possible onset of tics and developed tics within this period (n = 31); 
and first-degree relatives who did not develop tics and were ≥ 10 years old at their last assessment (n = 93). The relation-
ship between 25(OH)D and the presence and severity of tics, as well as comorbid obsessive–compulsive disorder (OCD) 
and attention-deficit/hyperactivity disorder (ADHD), were analysed controlling for age, sex, season, centre, latitude, family 
relatedness, and comorbidities. When comparing the CTD cohort to the unaffected cohort, the observed result was contrary 
to the one expected: a 10 ng/ml increase in 25(OH)D was associated with higher odds of having CTD (OR 2.08, 95% CI 
1.27–3.42, p < 0.01). There was no association between 25(OH)D and tic severity. However, a 10 ng/ml increase in 25(OH)
D was associated with lower odds of having comorbid ADHD within the CTD cohort (OR 0.55, 95% CI 0.36–0.84, p = 0.01) 
and was inversely associated with ADHD symptom severity (β = − 2.52, 95% CI − 4.16–0.88, p < 0.01). In conclusion, lower 
vitamin D levels were not associated with a higher presence or severity of tics but were associated with the presence and 
severity of comorbid ADHD in children and adolescents with CTD.
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Introduction
Chronic tic disorders (CTD) are neurodevelopmental 
conditions of which there are three types: chronic motor 
tic disorder, chronic vocal tic disorder, and Tourette Syn-
drome (TS) [3]. TS is characterised by the combined 
presence of multiple motor tics and at least one vocal tic 
and has an estimated prevalence of 0.3–0.9% [2, 19, 36]. 
A large proportion of individuals with CTD (~ 40–80%) 
have associated neuropsychiatric comorbidities; obses-
sive–compulsive disorder (OCD) and attention-deficit/
hyperactivity disorder (ADHD) are among the most com-
mon   [36]. Tics and their associated neuropsychiatric 
comorbidities, and ADHD in particular, have been shown 
to have a negative impact on quality of life and socioeco-
nomic status [1, 8, 9, 17].
The aetiology of CTD is not fully understood. Estimates 
of TS heritability range from 0.25 to 0.77 [29, 44], sug-
gesting that environmental factors also play a substantial 
role. CTD, like most other neuropsychiatric diseases, is a 
polygenic disorder [38]. Susceptibility genes so far identi-
fied include genes involved in multiple neurotransmitter 
systems, as well as the immune system [27, 42]. Envi-
ronmental factors include psychosocial stress, maternal 
smoking during pregnancy, and potentially infectious path-
ogens, although the evidence remains inconclusive [15].
One environmental factor of interest is vitamin D, a 
neurosteroid hormone, which plays an important role in 
skeletal health, as well as in neural and immune func-
tioning [10]. Vitamin D is a fat-soluble vitamin that is 
naturally present in a few foods and mainly produced in 
the skin when it is exposed to sunlight (UVB radiation). 
Its synthesis is therefore greatly influenced by season, 
latitude, air pollution, skin pigmentation, sunscreen use 
and aging, as well as by genetic factors, altered absorp-
tion/metabolism, and medication [20]. Vitamin D influ-
ences a large number of biological pathways; its receptors 
and activating enzyme (1α-hydroxylase) are widespread 
throughout the human brain, and it is thought to have neu-
rotropic and neuroprotective effects, influencing on neu-
rotransmission, neuroplasticity, and neuroinflammation 
[10, 20]. This may explain why hypovitaminosis D has 
been linked to several neuropsychiatric and neurological 
diseases such as mood disorders, schizophrenia, autism, 
multiple sclerosis, Parkinson’s disease, and Alzheimer’s 
disease [10, 20].
Theoretically, there are a number of ways in which 
vitamin D could be associated with CTD. Dopaminergic 
dysfunction is widely considered the pathological endpoint 
of CTD [23], though preceding pathogenic pathways are 
poorly understood. Vitamin D regulates gene expression 
of the rate-limiting enzyme, tyrosine hydroxylase, which 
modulates the production of dopamine, noradrenaline, and 
epinephrine [7]. Therefore, deficiency in vitamin D could 
contribute to dopaminergic dysfunction in CTD. Another 
possibility is that vitamin D is associated with raised 
inflammatory markers that have been reported in CTD 
[28]. Vitamin D has a largely anti-inflammatory effect 
and impacts on cellular und humoral immune responses 
[20]. Thus, it is plausible that low vitamin D contributes 
to inflammation in CTD or, conversely, that an overactive 
immune system in CTD leads to increased consumption of 
vitamin D, and thus lower levels (“reverse causation”) 
[20]. Vitamin D is also known to be important in brain 
development [10], and abnormalities in the maturation 
and structure of the brain are thought to be involved in 
the pathogenesis of CTD [13]. As the pathophysiology 
of CTD is not yet fully understood and the effects of vita-
min D are multiple throughout the body, it is difficult to 
pin-point a single possible underlying mechanism, though 
there are a number of ways in which the two could plau-
sibly be linked.
Evidence from one case–control study (n = 179) and a 
follow-up supplementation trial (n = 36) in Chinese chil-
dren suggested vitamin D may be associated with tic dis-
orders [24, 25]. These two studies reported lower levels of 
25-hydroxyvitamin D (25[OH]D) in children with tics com-
pared to healthy controls; a negative correlation between 
tic severity and 25(OH)D levels (r = − 0.32); and observed 
improvements in tic severity following 3-month supplemen-
tation in people with CTD who were insufficient or deficient 
in 25(OH)D at study entry (average reduction in severity 
score from [mean ± SD] 23 ± 5 to 13 ± 7, t = 10.15) [25]. 
OCD and ADHD, the most common comorbidities in CTD, 
have also been linked to lower levels of vitamin D [6, 21]. 
However, the result has been inconsistent [26, 43] and the 
salience of these observations remains to be understood.
Our study is part of the European Multicentre Tics in 
Children Studies (EMTICS) [39], a large prospective Euro-
pean multicentre study of children and adolescents with 
CTD and first-degree relatives of individuals with CTD who 
themselves did not have tics at study entry and were followed 
up for a maximum of 7 years to assess the possible onset 
of tics [39]. We hypothesised that: A. 25(OH)D is lower 
in individuals with CTD (CTD cohort) compared to first-
degree relatives of people with CTD but who themselves do 
not have tics (unaffected cohort); B. 25(OH)D is lower in 
first-degree relatives who developed tic disorders (tic onset 
cohort) compared to those who did not develop tics (unaf-
fected cohort) within the follow-up period; C. lower 25(OH)
D is associated with greater tic severity in individuals with 
CTD; D. lower 25(OH)D is associated with greater presence 
and severity of comorbid OCD and ADHD in individuals 
with CTD. This is the largest study to date to assess 25(OH)
D status in children and adolescents with CTD. It is unique 
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in its assessment of 25(OH)D in first-degree relatives at risk 
of developing tics; and it is the first study to investigate an 
association between 25(OH)D levels and the severity of psy-
chiatric comorbidities in CTD.
Methods
Participants
Participants were from the European Multicentre Tics in 
Children Studies (EMTICS) [39], a prospective longitu-
dinal observational study involving 16 centres located in 
nine countries across Europe and in Israel. The structure 
of the study was previously described in detail (see [39]). 
EMTICS recruited two cohorts: the COURSE study, 703 
children and adolescents (3–16 years) with an established 
diagnosis of CTD according to DSM-IV-TR (note that six 
participants enrolled in the study were removed as they did 
not have a CTD) [2]; and the ONSET study, an at-risk cohort 
comprising 259 first-degree relatives of children with CTD 
(3–10 years), without tics (note that one of the 260 partici-
pants enrolled in the study was recently removed due to tics 
prior to study entry). The at-risk cohort was followed up for 
3 years to assess the onset of tics according to regular study 
protocol, during which time 61 tic onsets were identified. 
All unaffected children were reassessed via a brief telephone 
interview after the study ended, which identified seven addi-
tional confirmed tic onsets (n = 68 in total) in 2019/2020; 36 
children could not be recontacted.
This study makes comparisons between participants with 
tic disorders and an unaffected group. The mean age of tic 
onset in the EMTICS ONSET cohort was 7.93 years old 
(SD 2.00, range 3.52–13). Therefore, there was a risk that 
children in the unaffected cohort might develop tics beyond 
the study period. To mitigate this risk, we only included par-
ticipants who did not develop tics and were at least 10 years 
of age at the time of the extended follow-up reassessment 
or, for those that could not be reassessed, at least 10 years of 
age at the time of the last visit during the regular study term.
This cross-sectional study represented a sub-sample of 
the EMTICS cohorts based on available serum samples for 
25(OH)D analysis. This included: baseline samples for 327 
participants with CTD (CTD cohort); baseline samples for 
93 participants who did not develop tics and were 10 years of 
age or older at the time of their last assessment (unaffected 
cohort); and samples taken at the time of tic onset for 31 
participants who developed tics within the 3-year regular 
study period (tic onset cohort). (Note that no serum samples 
were taken during the telephone reassessment period and 
therefore the seven children who developed tics after the 
regular study period could not be included in the analyses 
of this study).
The regular study period took place from January 2013 to 
June 2018, and the final telephone reassessment concluded 
in May 2020. The study was approved by the Institutional 
Review Boards of the participating centres. Parents and their 
child(ren) provided written informed consent and assent 
according to the appropriate ethical regulations.
Clinical assessment
An established diagnosis of CTD, OCD, and ADHD was 
confirmed by study clinicians according to DSM-IV-TR cri-
teria [2]. Our main outcome measure for current tic sever-
ity was the Yale Global Tic Severity Scale (YGTSS) [22]. 
Study clinicians also rated the Clinical Global Impression 
Scale Severity (CGI) for tic severity during the previous 
week [14]. The Children’s Yale-Brown Obsessive–Compul-
sive Scale (CY-BOCS) was used to rate obsessive–compul-
sive symptom severity [12, 37]. The parent-reported Swan-
son, Nolan and Pelham-version IV rating scale (SNAP-IV) 
assessed ADHD symptom severity [41]. As SNAP-IV is 
parent-rated and not clinician assessed, we additionally used 
the DSM-IV-TR ADHD symptom count as a second measure 
of ADHD severity.
Analysis of 25‑hydroxyvitamin D (25(OH)D)
Serum samples were collected at study entry (i.e., at base-
line) for the CTD cohort and for the unaffected cohort, 
whereas, for the tic onset cohort, we used serum samples 
that were taken at the time of tic onset. All samples were 
sent to the Department of Laboratory Medicine, Munich 
(LMU). The samples were stored at − 80 °C until the time 
of analysis. The level of 25(OH)D was measured in the 
ISO 15189 accredited lab on a DiaSorin Liaison analyser 
using chemiluminescent immunoassay technology. Serum 
samples were processed according to the manufacturer’s 
instructions. The range of the assay was 4 ng/ml (10 nmol/l) 
up to 150 ng/ml (375 nmol/l).
Hypovitaminosis-D was reported at levels under 20 ng/
ml (50 nmol/l) in accordance with the US Endocrine Soci-
ety [16], with levels ≤ 10 ng/ml (≤ 25 nmol/l) considered 
deficient and between 10 and 20 ng/ml (25–50 nmol/l) insuf-
ficient [16].
To correct for seasonal variation in 25(OH)D levels, 
we used a previously described method [30]. The follow-
ing equation was used to predict 25(OH)D levels for any 
given day of the year for each cohort (y = 25(OH)D level and 
t = day of year, e.g., for January 1st, t = 0):
The difference between predicted 25(OH)D levels on a 
given day and the individual’s actual level gave a residual 
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value of 25(OH)D controlling for season. In our analyses, 
we used multilevel models with site as a cluster variable to 
account for all differences between study centres, includ-
ing, for example, ambient levels of vitamin D associated 
with living at different latitudes.
Statistical analysis
Since this was a multicentre study involving siblings, par-
ticipants were clustered both within centres and as fami-
lies. Therefore, both centre and family relatedness were 
used as cluster variables in all multilevel models. Gener-
alised linear mixed models were used to assess whether 
25(OH)D levels were associated with: the odds of hav-
ing a CTD compared to the unaffected cohort; tic onset 
compared to the unaffected cohort; and the presence of 
comorbid OCD or ADHD compared to those with CTD 
only. Multilevel models were used to investigate whether 
25(OH)D levels were associated with tic severity (YGTSS 
and CGI) as well as the severity of comorbid OCD (CY-
BOCS) and ADHD (SNAP-IV and DSM-IV-TR) symp-
toms. OCD and ADHD symptom severity scores were 
taken from the entire CTD cohort and not just those who 
met the criteria for each comorbid diagnosis.
Participants’ seasonally adjusted 25(OH)D level was the 
primary predictor variable in all analyses. To give a more 
clinically relevant outcome, adjusted 25(OH)D was divided 
by 10, so that one-unit change in the predictor variable was 
equal to 10 ng/ml 25(OH)D, as opposed to 1 ng/ml. As a 
secondary analysis, we ran all models with 25(OH)D as a 
binary predictor variable, with 25(OH)D insufficiency meas-
ured as ≤ 20 ng/ml and sufficiency as > 20 ng/ml. The aver-
age serum 25(OH)D was adjusted for by centre in order to 
disentangle contextual effects from person-level effects [35]. 
Age, sex, and the presence of a comorbidity (OCD and/or 
ADHD) were also entered as covariates.
As a sensitivity analysis, we re-analysed the generalised 
linear models in subsamples matched on age and sex [par-
ticipants with CTD and unaffected (n = 93);  participants 
with tic onset and unaffected (n = 31); CTD participants 
with OCD and without OCD (n = 95); CTD participants 
with ADHD and without ADHD (n = 79)]. Subsamples were 
matched using propensity score matching in R [34].
The average predicted level of 25(OH)D is the same in 
May as it is at the end of November because these months 
fall at the halfway point between August (when levels are 
highest) and March (when they are lowest). Therefore, 
we added the average predicted 25(OH)D level for May/
November to each individual’s residual value to estimate the 
proportion of participants in each cohort who would have 




Demographic and clinical characteristics of participants 
are shown in Table 1. The vast majority of the CTD cohort 
were diagnosed with TS (n = 298; 91.1%) and a minority 
with a motor CTD (n = 28; 8.6%) or vocal CTD (n = 1; 
0.3%).
Levels of 25(OH)D and prevalence 
of hypovitaminosis D in CTD, unaffected, and tic 
onset cohort
Levels of 25(OH)D fluctuated according to season with 
the lowest levels in early spring and highest levels in late 
summer for all cohorts as shown in Fig. 1.
Contrary to our hypothesis, the unaffected cohort, who 
did not develop tics, had lower serum 25(OH)D levels than 
individuals in the CTD cohort and tic onset cohort. The 
sinusoidal regression model used to adjust for seasonal 
variation predicted hypovitaminosis D (25[OH]D < 20 ng/
ml) in 43.7% of the unaffected cohort, 25.8% of the tic 
onset cohort, and 27.2% of the CTD cohort for 6 months 
of the year (December–May).
As shown in Table 2, a 10 ng/ml increase in 25(OH)D 
was associated with higher odds of having a CTD diagno-
sis when compared to the unaffected cohort (OR 2.08, 95% 
CI 1.27–3.42, p < 0.01). The change in probability of hav-
ing CTD as 25(OH)D levels increase is shown in Fig. 2. 
However, this association was no longer significant when 
tested for in an age- and sex-matched subgroup (Table 4, 
Appendix 1).
There was no significant association between 25(OH)
D levels and the first development of tics when compar-
ing the tic onset cohort to the unaffected cohort (p = 0.10, 
Table 2).
No association between 25(OH)D levels 
and the severity of tics in CTD cohort
As shown in Table 3, we found no significant association 
between 25(OH)D levels and tic severity as measured by 
both YGTSS (p = 0.84) and CGI (p = 0.91).
Association of 25(OH)D levels with comorbid ADHD 
and OCD in CTD cohort
OCD: as shown in Table 2 and Fig. 2, a 10 ng/ml increase 
in 25(OH)D was associated with higher odds of having a 
comorbid OCD diagnosis in the CTD cohort (OR 1.46, 
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95% CI 1.04 to 2.04, p = 0.03). However, we found no sig-
nificant association between 25(OH)D and OCD symptom 
severity among the CTD cohort (p > 0.05) (Table 3).
ADHD: A 10 ng/ml increase in 25(OH)D was associ-
ated with lower odds of having an ADHD diagnosis in the 
CTD cohort (OR 0.55, 95% CI 0.36–0.84, p = 0.01) (Table 2 
Table 1  Demographic and 
clinical characteristics
Unaffected cohort (did not develop tics by end of the study or reassessment period  and ≥ 10  years old); 
non-white (mixed, Middle Eastern, North African, Asian or of unknown ancestry); NOS (tic disorder con-
firmed by type was ‘not otherwise specified’ by study clinicians)







Age (years) (mean ± SD) 10.9 (± 2.72) 7.55 (± 1.83) 7.68 (± 1.76)
Sex n (%)
 Male 247 (75.5) 22 (71.0) 37 (39.8)
 Female 80 (24.5) 9 (29.0) 56 (60.2)
Ethnicity n (%)
 White 301 (92.0) 25 (80.6) 80 (86.0)
 Non-white 26 (8.0) 6 (19.4) 13 (14.0)
Tic Disorder n (%)
 Tourette Syndrome 298 (91.1) 8 (25.8)
 Chronic Motor Tic Disorder 28 (8.6) 7 (22.6)
 Chronic Vocal Tic Disorder 1 (0.3)
 Transient Tic Disorder 9 (29.0)
 Tic Disorder—NOS 7 (22.6)
Comorbidities n (%)
 OCD 95 (29.1)
 ADHD 79 (24.2) 2 (6.5) 11 (11.8)
Seasonally Adjusted 25(OH)D n (%)
 Insufficient (10–20 ng/ml; 25–50 nmol/l) 89 (27.2) 8 (25.8) 35 (37.6)
 Deficient (≤ 10 ng/ml; ≤ 25 nmol/l) 3 (0.9) 0 (0.0) 2 (2.2)
 Median (interquartile range) 24.7 (19.2–29.8) 24.3 (19.6–33.7) 21.6 (17.0–27.3)
Fig. 1  Fitted values from the 
sinusoidal regression model of 
vitamin D levels in terms of 
CTD/tic onset/unaffected and 
the day of the year on which the 
sample was taken (day 0 = Janu-
ary 1). This model was used to 
create a deseasonalised vitamin 
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and Fig. 2). As shown in Fig. 3, there was also an inverse 
association between an increase of 10 ng/ml of 25(OH)
D and SNAP-IV parent-rated ADHD symptom severity 
(β = − 2.52, S.E. = 0.83, p < 0.01), as well as for DSM-IV-
TR ADHD total symptom count (β = − 1.02, S.E. = 0.33, 
p < 0.01) (Table 3). The association existed for the ADHD 
inattentive symptoms dimension, both for the SNAP-IV 
(β = − 1.75, S.E. = 0.47, p < 0.01) and the DSM-IV-TR count 
(β = − 0.57, S.E. = 0.21, p = 0.01). For hyperactive–impul-
sive symptoms, the DSM-IV-TR score was significant 
(β = − 0.42, S.E. = 0.17, p = 0.01), but was not significant 
for SNAP-IV hyperactive–impulsive symptoms (β = − 0.77, 
S.E. = 0.44, p = 0.08) (Table 3).
Age- and sex-matched sensitivity analyses: As shown in 
Table 4 (Appendix 1), when we ran the generalised linear 
models in age- and sex-matched subgroups, an increase in 
25(OH)D was no longer associated with higher odds of hav-
ing CTD (p = 0.46), but remained significantly associated 
with higher odds of having comorbid OCD (OR 1.83, 
p = 0.01) and with lower odds of having comorbid ADHD 
(OR 0.55, p = 0.02) within the CTD cohort. (Note matching 
the cohorts reduced the sample size and, therefore, the power 
to detect significant results.)
25(OH)D sufficiency/insufficiency as a binary predictor 
variable: As shown in Tables 5 and 6 (Appendix 1), 25(OH)
D sufficiency (> 20 ng/ml) was associated with higher odds 
of having CTD compared to the unaffected cohort (OR 3.05, 
p = 0.01). Whereas, 25(OH)D sufficiency was not associated 
with a change in the odds of having OCD within the CTD 
group (p > 0.05). However, 25(OH)D sufficiency was associ-
ated with lower odds of having comorbid ADHD (OR 0.54, 
p = 0.05) and a decrease in ADHD symptom severity on total 
SNAP (β = − 4.21, S.E. = 1.49, p = 0.01) and DSM-IV-TR 
(− 1.25, p = 0.04), as well as inattentive domains, though 




In this multicentre study of children and adolescents with 
CTD and first-degree relatives of individuals with CTD, 
lower levels of 25(OH)D were not associated with a higher 
presence or severity of tics. Contrary to our hypothesis, first-
degree relatives who themselves did not develop tics within 
the study period (unaffected cohort) had lower 25(OH)
D levels than participants with CTD. Additionally, there 
was no significant difference in 25(OH)D status between 
at-risk individuals who went on to develop tics within the 
study period (tic onset cohort) compared to those who did 
not (unaffected cohort). However, serum 25(OH)D was 
associated with psychiatric comorbidities in CTD: higher 
levels were associated with lower odds of having comor-
bid ADHD and inversely associated with ADHD symptom 
severity. Conversely, higher serum 25(OH)D was associ-
ated with higher odds of having comorbid OCD, but was 
not associated with OCD symptom severity.
Vitamin D deficiency is common in Europe and world-
wide [4, 5, 32]. A recent meta-analysis combined data from 
18 European studies (for total n = 55,844) and gave an over-
all pooled estimate of vitamin D deficiency (< 12 ng/ml), 
irrespective of the age, ethnicity, and latitude of the study 
population, of 13.0% [5]. This is a comparatively larger pro-
portion than observed in any of the cohorts included in this 
study. This estimate is, therefore, in line with our observa-
tion that children with CTD are no more likely to have vita-
min D deficiency than the general population. Nonetheless, 
6.0% of participants in this study were deficient at the time 
of serum collection and would require treatment according 
Table 2  Effect of 25(OH)D on the presence of CTD, comorbid OCD, 
and ADHD
a The dependent variable is the presence of CTD, OCD, or ADHD 
and the primary predictor variable is adjusted 25(OH)D (1-unit 
change = 10 ng/ml), while sex, age, and comorbidity, other than that 
being tested, were also entered as covariates. The odds are calculated 
for 1-unit change (i.e., 10 ng/ml) in our predictor variable
CTD chronic tic disorder, OCD obsessive–compulsive disorder, 
ADHD attention-deficit hyperactivity disorder
*The significant difference with p < 0.05
Dependent  variablea OR 95% CI p
CTD 2.08 1.27–3.42  < 0.01*
Tic onset 1.73 0.91–3.29 0.10
CTD comorbid OCD 1.46 1.04–2.04 0.03*

































Fig. 2  Estimated change in probability of having a CTD, OCD, 
or ADHD diagnosis as 25(OH)D (ng/ml) increases. As 25(OH)D 
increases, the probability of CTD and OCD increases, whereas for 
ADHD, the probability decreases
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to the National Institute of Health and Care Excellence 
(NICE) guidelines (< 10 ng/ml; 25 nmol/l) [31]. It therefore 
remains important to highlight the risk vitamin D deficiency 
poses to children and adolescents in Europe, particularly 
as cost-effective prevention strategies, such as altered diet, 
vitamin D supplements, and changes in behavior related to 
sun exposure are so easy to implement.
Higher serum 25(OH)D was associated with higher odds 
of having CTD compared to the unaffected cohort in this 
study. However, this association was no longer significant 
when tested for in an age- and sex-matched subgroup. 
Matching substantially reduced the size of our population 
sample, and therefore, loss of power may explain why we no 
longer observed a significant result. However, it is also pos-
sible that the difference in 25(OH)D between the two groups 
was largely due to differences in age and/or sex. Changes 
in parent and/or child behavior as a direct result of their 
diagnosis, i.e., “reverse causation”, is another potential fac-
tor. Age, sex, and diagnosis may influence activity, sunlight 
exposure, diet, and use of supplementation as parents and/or 
clinicians may be more likely to check and thus attempt to 
remediate vitamin deficiencies in patients with CTD. Lack 
of data on vitamin D supplementation usage and sun expo-
sure was a limitation of this study, and should be recorded 
and controlled for in future studies.
Our findings differ from a case–control study and a fol-
low-up supplementation trial in Chinese children, which 
reported lower levels of 25(OH)D in children with tics; a 
negative correlation between tic severity and 25(OH)D lev-
els; and observed improvements in tic severity upon 25(OH)
Table 3  Effect of 25(OH)
D on Tic, OCD, and ADHD 
Symptom Severity
a The dependent variable is symptom severity. The primary predictor variable is adjusted 25(OH)D (1-unit 
change = 10  ng/ml), while age, sex, and comorbidity, other than that being tested, were also entered as 
covariates. β coefficient is calculated for 1-unit change (i.e., 10 ng/ml) in our predictor variable
YGTSS Yale Global Tic Severity Scale, OCD obsessive–compulsive disorder, CY-BOCs Children’s Yale-
Brown Obsessive–Compulsive Scale, ADHD attention-deficit hyperactivity disorder, DSM-IV-TR diagnos-
tic and statistical manual of mental disorders 4th ed., text revision, SNAP-IV Swanson, Nolan, and Pelham 
Questionnaire IV
*The significant difference with p < 0.05
Dependent  variablea β SE 95% CI p
Tic severity
 YGTSS:Total 0.11 0.51 − 0.90 to 1.11 0.84
 YGTSS Motor 0.03 0.29 − 0.54 to 0.61 0.91
 YGTSS Vocal 0.08 0.34 − 0.60 to 0.76 0.82
 CGI − 0.01 0.06 − 0.13 to 0.11 0.91
OCD
 CYBOCs Total 0.55 0.49 − 0.42 to 1.51 0.27
 CYBOCs Obsessions 0.25 0.26 − 0.26 to 0.77 0.33
 CYBOCs Compulsions 0.30 0.34 − 0.37 to 0.98 0.37
ADHD
 DSM-IV-TR Total − 1.02 0.33 − 1.67 to − 0.37  < 0.01*
 DSM-IV-TR Inattentive − 0.57 0.21 − 0.97 to − 0.16 0.01*
 DSM-IV-TR Hyperactive/Impulsive − 0.42 0.17 − 0.75 to − 0.09 0.01*
 SNAP Total − 2.52 0.83 − 4.16 to − 0.88  < 0.01*
 SNAP Inattentive − 1.75 0.47 − 2.68 to − 0.82  < 0.01*
 SNAP Hyperactive/Impulsive − 0.77 0.44 − 1.64 to 0.10 0.08
Fig. 3  The graph on the 
left shows that as 25(OH)D 
increases, severity of ADHD 
as measured by DSM-IV-TR 
decreases. The graph on the 
right shows that as 25(OH)D 
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D supplementation [24, 25]. It is possible that ethnicity and 
genetic susceptibility played a role in these divergent results. 
Another difference between this study and the two previous 
ones is that this study focussed on the differences between 
children with CTD and first-degree relatives. Therefore, 
factors that influence 25(OH)D levels, such as environ-
ment and genetics, were more likely to be shared between 
cohorts which could have potentially reduced confounding 
influences on 25(OH)D. The key limitations of the supple-
mentation trial in Chinese children, as highlighted by the 
authors themselves, were that it was open-label and almost 
half of the children did not complete treatment or were lost 
to follow-up [25]. Therefore, the observed improvement in 
tic severity following 25(OH)D supplementation (n = 36) 
could have been due to other factors influencing partici-
pation including increased parental support or placebo. 
As mentioned above, it is important to emphasise that all 
children and adolescents deficient or insufficient in 25(OH)
D should be given appropriate supplementation. However, 
our findings suggest more robust evidence should be gath-
ered before further supplementation trials are implemented 
in children with CTD as resources may be better directed 
elsewhere.
For comorbid OCD in participants with CTD, we found 
the opposite result to our hypothesis. We observed a 10 ng/
ml increase in 25(OH)D levels was associated with higher 
odds of having comorbid OCD (OR 1.46, 95% CI 1.04–2.04, 
p = 0.03). However, when we looked at 25(OH)D insuffi-
ciency versus sufficiency as a binary predictor variable, 
25(OH)D sufficiency was no longer a significant predictor 
Table 4  Sensitivity analysis with age- and sex-matched subgroups
a The dependent variable is the presence of CTD, tic onset, OCD or 
ADHD and the primary predictor variable is adjusted 25(OH)D 
(1-unit change = 10 ng/ml). Sex, age and comorbidity, other than that 
being tested, were also entered as covariates. The odds are calculated 
for 1-unit change (i.e., 10 ng/ml) in our predictor variable
CTD chronic tic disorder, OCD obsessive–compulsive disorder; 
ADHD attention-deficit hyperactivity disorder
*The significant difference with p < 0.05
Effect of 25(OH)D on the presence of CTD, comorbid OCD and 
ADHD
Dependent  variablea OR 95% CI p
CTD 1.18 0.75–1.86 0.46
Tic onset 2.11 0.85–5.26 0.11
CTD comorbid OCD 1.83 1.20–2.80 0.01*
CTD comorbid ADHD 0.55 0.34–0.91 0.02*
Table 5  Effect of 25(OH)D sufficient versus insufficient on the pres-
ence of CTD, comorbid OCD, and ADHD
a The dependent variable is the presence of CTD, tic onset, OCD, or 
ADHD and the primary predictor variable is a binary measure of 
25(OH)D insufficiency/sufficiency, where adjusted 25(OH)D insuf-
ficiency (≤ 20 ng/ml) = 0 and sufficiency (> 20 ng/ml) = 1. Thus, the 
odds ratio is calculated for those sufficient as compared to insuffi-
cient, i.e., the odds of having CTD were higher (OR = 3.05) in those 
with sufficient 25(OH)D compared to those with insufficient levels, 
whereas the odds of having ADHD were lower (OR = 0.54) in those 
with sufficient 25(OH)D compared to those with insufficient 25(OH)
D. Sex, age,and comorbidity, other than that being tested, were also 
entered as covariates
CTD chronic tic disorder, OCD obsessive–compulsive disorder, 
ADHD attention-deficit hyperactivity disorder)
*The significant difference with p < 0.05
Dependent  variablea OR 95% CI p
CTD 3.05 1.39–6.71 0.01*
Tic onset 2.00 0.70–5.72 0.19
CTD comorbid OCD 1.15 0.63–2.11 0.65
CTD comorbid ADHD 0.54 0.29–1.00 0.05*
Table 6  Effect of 25(OH)D sufficient versus insufficient on Tic, OCD 
and ADHD symptom severity
a The dependent variable is the presence of CTD, tic onset, OCD, or 
ADHD and the primary predictor variable is a binary measure of 
25(OH)D insufficiency/sufficiency, where adjusted 25(OH)D insuf-
ficiency (≤ 20  ng/ml) = 0 and sufficiency (> 20  ng/ml) = 1. β coef-
ficients were calculated for the difference between insufficiency 
(≤ 20  ng/ml) and sufficiency (> 20  ng/ml), i.e., SNAP-total score 
was less severe (β – 4.21) in those with sufficient compared to those 
with insufficient 25(OH)D. Sex, age, and comorbidity, other than that 
being tested, were also entered as covariates
YGTSS Yale Global Tic Severity Scale 0, OCD obsessive–compul-
sive disorder, CY-BOCs Children’s Yale-Brown Obsessive–Compul-
sive Scale, ADHD attention deficit hyperactivity disorder, DSM-IV-
TR diagnostic and statistical manual of mental disorders 4th ed., text 
revision, SNAP-IV Swanson, Nolan, and Pelham Questionnaire IV
*The significant difference with p < 0.05
Dependent  variablea β SE 95% CI p
Tic Severity
 YGTSS:Total 0.85 0.91 − 0.94 to 2.64 0.35
 YGTSS Motor 0.19 0.52 − 0.83 to 1.21 0.71
 YGTSS Vocal 0.45 0.62 − 0.77 to 1.66 0.72
 CGI − 0.10 0.11 − 0.32 to 0.11 0.34
OCD
 CYBOCs Total − 0.39 0.90 − 2.16 to 1.39 0.67
 CYBOCs Obsessions 0.02 0.49 − 0.52 to 1.40 0.37
 CYBOCs Compulsions − 0.45 0.62 − 1.67 to 0.77 0.47
ADHD
 DSM-IV-TR Total − 1.25 0.61 − 2.05 to − 0.05 0.04*
 DSM-IV-TR Inattentive − 0.72 0.36 − 1.43 to − 0.01 0.05*
 DSM-IV-TR − 0.46 0.31 − 1.06 to − 0.15 0.14
Hyperactive/Impulsive
 SNAP Total − 4.21 1.49 − 7.14 to 1.28 0.01*
 SNAP Inattentive − 3.14 0.80 − 4.73 to − 1.55  < 0.01*
 SNAP Hyperactive/
Impulsive
− 1.39 0.79 − 2.94 to 0.16 0.08
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of OCD. Furthermore, 25(OH)D sufficiency was not associ-
ated with the severity of comorbid OCD symptoms. Studies 
investigating 25(OH)D levels in individuals with OCD but 
without comorbid CTD have so far produced mixed results 
[43]. Again, differences in parent and/or child behavior in 
response to diagnoses (“reverse causation”) may explain 
why we observed increased 25(OH)D levels in our study. 
Nonetheless, given that there seems to be no association 
with the severity of OCD symptoms and 25(OH)D levels, it 
is unlikely that low 25(OH)D levels share a causal relation-
ship with OCD symptoms.
However, a 10 ng/ml increase in 25(OH)D was associated 
with lower odds of having comorbid ADHD in the CTD 
cohort (OR 0.55, 95% CI, 0.36–0.84, p = 0.01). In addi-
tion, we observed that for an increase of 10 ng/ml 25(OH)
D, the SNAP-IV ADHD scale decreased by an average of 
2.52. A clinically meaningful change in ADHD symptoms 
is often considered as a 30% reduction [40]. In our cohort, 
this equates to an average 5.6-point reduction in SNAP-
IV (range 0–54) which was associated with a 22.4 ng/ml 
increase in 25(OH)D. The physiological relevance of this 
degree of increase is not fully understood; current guidelines 
on 25(OH)D levels are based on its role in bone metabolism, 
but less is known about the impact of changes in serum lev-
els in relation to its involvement in immune mechanisms, 
brain development, and neurotransmission. A recent meta-
analysis, which included 10,334 children and adolescents, 
found that children with ADHD had lower levels of 25(OH)
D on average when compared to healthy controls [18]. How-
ever, our study is the first to assess 25(OH)D in the con-
text of comorbid ADHD in children with CTD. Comorbid 
ADHD is common in children with CTD (40–80%) [11]. 
Evidence of possible genetic, and neurobiological and neu-
rophysiological overlap between CTD and ADHD indicate 
that the two disorders are highly interrelated [11], and those 
with both CTD and ADHD have a substantially increased 
psychiatric and functional burden and a lower quality of 
life [33]. Therefore, understanding and managing ADHD 
symptoms in children with CTD is of clinical importance. 
The results of this study indicate that vitamin D status may 
be helpful as a marker of ADHD disease activity in children 
with CTD. While further evidence is required, it is possible 
that supplementation may prove to be beneficial in a pro-
portion of children with ADHD symptoms; however, the 
benefits may well be restricted to those who are deficient.
Limitations
One limitation of this study was that we were unable to com-
pare our findings to a healthy control cohort and that we had 
to control for age and sex in all our models. The EMTICS 
cohorts were not set up as a regular case–control study and 
an assessment of vitamin D status was not included in the 
original research plan. Nonetheless, 25(OH)D remained 
significantly associated with the presence and severity of 
comorbid ADHD when we conducted a sensitivity analysis 
using age- and sex-matched subgroups.
Another limitation of this study was that serum samples 
for 25(OH)D analysis were only available for a small number 
of participants with tic onset (n = 31). Moreover, our cross-
sectional study is not useful for drawing inferences about the 
direction of effects between hypovitaminosis D and comor-
bid ADHD in children with CTD. Prospective longitudinal 
studies are needed to determine whether lower vitamin D 
levels predispose individuals with CTD to develop comorbid 
ADHD; or whether those with comorbid ADHD have lower 
levels of vitamin D due to differences in behavior, immune 
activation, metabolism (reverse causation); or the two are 
indirectly linked via  shared mechanisms. Our study also 
lacked complementary data on diet, parathyroid hormone 
levels, calcium levels, dairy intake, daily outdoor activity, 
sunlight exposure, body mass index, puberty stage, supple-
mentation during infancy, medication, socioeconomic status, 
and screening for comorbid anxiety and depression, which 
should be considered in future research.
Conclusion
To our knowledge, this is the largest study to date to investi-
gate 25(OH)D status in children and adolescents with CTD 
and the first to evaluate 25(OH)D alongside the onset of 
tics in an at-risk population. It is also the first to investigate 
25(OH)D levels in relation to comorbid ADHD and OCD 
in CTD. In contrast to earlier observations, lower serum 
25(OH)D was not associated with a higher presence or 
severity of tics. However, our data showed an inverse asso-
ciation between serum 25(OH)D levels and both the pres-
ence and severity of comorbid ADHD, and this relationship 
warrants further investigation.
Appendix
See Tables 4, 5 and 6.
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